Esophageal carcinoma (squamous + adeno) · line 1 · Pembrolizumab + cisplatin + fluorouracil
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-PEMBRO-CISPLATIN-5FU-ESOPH |
| ID | IND-ESOPH-METASTATIC-1L-PEMBRO-CHEMO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-ESOPHAGEAL |
| Sources | SRC-ESMO-ESOPHAGEAL-2024 SRC-KEYNOTE-590-SUN-2021 SRC-NCCN-ESOPHAGEAL-2025 |
Notes
REG-PEMBRO-CISPLATIN-5FU-ESOPH (pembrolizumab 200mg q3w + cisplatin 80mg/m² D1 + 5-FU 800mg/m²/d D1-5 q3w) needs to be authored. Carboplatin can substitute for cisplatin in cisplatin-ineligible patients (AUC 5 q3w); less evidence but acceptable in clinical practice. Maximum 35 cycles pembrolizumab (per KEYNOTE design); cisplatin typically given for 6 cycles then 5-FU+pembro maintenance per institutional practice.
Used By
Algorithms
ALGO-ESOPH-METASTATIC-1L- ALGO-ESOPH-METASTATIC-1L